Heart failure & cardiomyopathiesCohort study
Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry
- Registry-based cohort study
- international
- multivariable regression
Authors' conclusion
Non-HF polypharmacy in HF is common worldwide, particularly in high-income regions.
Study context
- Population
- Patients hospitalised for acute heart failure (HF) in the international REPORT-HF registry
- Participants
- 18,030 patients
- Exposure
- Non-HF polypharmacy and hyper-polypharmacy vs no polypharmacy
- Outcome
- Prevalence, clinical correlates and 1-year mortality associations of non-HF polypharmacy
- Follow-up
- 1 year
Main finding
As reported in the abstract
Prevalence of non-HF polypharmacy and 1-year mortality
Each group vs no polypharmacyHazard ratio (95% CI)
Polypharmacycrude, 1-year mortality
1.16(1.08–1.25)
Hyper-polypharmacycrude, 1-year mortality
1.46(1.31–1.63)
Hyper-polypharmacyadjusted, 1-year mortality
1.16(1.01–1.33)
Observational data: associations, not effects.
Further findings
Correlates and medication patterns of non-HF polypharmacy
- More common in older white patients from high-income countries, with preserved EF and high comorbidity burden
- Greater non-HF medication use: less likely to receive guideline-directed HF medications and more likely to take medications that can worsen HF
Original publication
Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry. Eur J Heart Fail. Published 1 October 2025. doi:10.1002/ejhf.70056
Summarised from the published abstract; every number is checked against it